Endocyte stops enrollment in Phase Ia/Ib solid tumor trial of EC1456
Endocyte Inc. (NASDAQ:ECYT) will stop enrollment in the Phase Ib portion of an open-label, U.S. Phase Ia/Ib trial of twice-weekly 6 mg/m2 EC1456 in up to 40 folate receptor-positive non-small cell lung cancer (NSCLC) patients. The company said “multiple dosing schedules did not yield the level of clinical activity necessary to support continued advancement.” The trial’s dose-escalation Phase Ia portion evaluated EC1456 in patients with advanced solid tumors irrespective of folate receptor expression.
EC1456 is a small molecule drug conjugate consisting of folate (vitamin B9) linked to tubulysin B hydrazide (TubBH). The trial's primary endpoints included maximum tolerated dose (MTD), recommended Phase II dose and safety for the Phase Ia portion and response for the Phase Ib portion...
BCIQ Company Profiles